

Oncology Today with Dr Neil Love: Integrating Antibody-Drug Conjugates into the Management of HR-Positive and Triple-Negative Metastatic Breast Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. Sacituzumab govitecan targets which of the following proteins?**
 - a. PD-L1
 - b. TROP2**
 - c. HER2
 - d. HER3
- 2. The Phase III DESTINY-Breast06 trial examined the efficacy of T-DXd for which of the following subtypes of HR-positive breast cancer?**
 - a. HER2-overexpressing (IHC 3+)
 - b. HER2-low (IHC 1+ or 2+)
 - c. HER2-ultralow (any IHC staining in up to 10% of cells)
 - d. Both HER2-overexpressing and HER2-ultralow
 - e. Both HER2-low and HER2-ultralow**
- 3. In the Phase III TROPiCS-02 trial, which of the following patient groups saw the greatest benefit in progression-free survival when treated with sacituzumab govitecan?**
 - a. Efficacy was comparable across all subgroups
 - b. The HER2-low (IHC1+ or 2+) population**
 - c. The HER2-negative (IHC 0) population
- 4. Which of the following toxicities associated with T-DXd treatment were most commonly observed as part of the Phase III DESTINY-Breast04 trial?**
 - a. Neurological disorders
 - b. Gastrointestinal disorders**
 - c. Blood and lymphatic system disorders
 - d. Interstitial lung disease and pneumonitis
- 5. What was the approximate reduction in the risk of disease progression or death with datopotamab deruxtecan among patients with HR-positive, HER2-negative breast cancer enrolled in the Phase III TROPION-Breast01 study?**
 - a. 16%
 - b. 36%**
 - c. 56%
 - d. 76%